 | Up a level |
Gencer, B; Carballo, D; Nanchen, D; Koskinas, K; Klingenberg, R; Raeber, L; Auer, R; Carballo, S; Heg, D; Windecker, S; Luscher, T F; Matter, C M; Rodondi, N; Mach, F (21 October 2019). P1222Intensification of lipid lowering therapy before and after publication of the IMPROVE-IT trial: A temporal analysis from the SPUM-ACS cohort. European Heart Journal, 40(Supplement_1), p. 678. 10.1093/eurheartj/ehz748.0180
Denegri, A; Magnani, G; Rossi, V A; Raeber, L; Windecker, S; Gencer, B; Mach, F; Rodondi, N; Heg, D; Nanchen, D; Matter, C M; Luescher, T F (October 2019). P6440The perils of polyvascular disease with concomitant type 2 diabetes in a real-world cohort of patients with acute coronary syndrome. European Heart Journal, 40(Supplement_1), p. 4040. 10.1093/eurheartj/ehz746.1034
Canivell, S.; Muller, O.; Gencer, B.; Heg, D; Klingenberg, R.; Raeber, L; Carballo, D.; Matter, C.M.; Luescher, T.F.; Windecker, S; Mach, F.; Rodondi, N; Nanchen, D. (August 2017). 2191 Impact of non-cardiovascular multimorbidity after acute coronary syndrome. European Heart Journal, 38(suppl_1), ehx502.2191. Oxford University Press 10.1093/eurheartj/ehx502.2191
Koskinas, K C; Gencer, B.; Raeber, L; Karagiannis, A.; Nanchen, D.; Carballo, D.; Carballo, S.; Klingenberg, R.; Heg, D; Matter, C.; Luscher, T.F.; Rodondi, N; Windecker, S; Mach, F. (August 2017). P169 Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes. European Heart Journal, 38(suppl_1), ehx501.P169. Oxford University Press 10.1093/eurheartj/ehx501.P169
